- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
This study is for adults in the UK with a type of cancer called follicular lymphoma that has come back or not responded to previous treatments. It investigates a new cell therapy called tisagenlecleucel to see how well it works and if it's safe.
For: Adult patients with refractory or relapsed follicular lymphomaItaly · Belgium · Germany